Bioreactors Market is expected to reach US$ 6,570.76 million by 2030

According to our new research study on “Bioreactors Market Forecast to 2030 – Global Analysis – by Scale, Application, Technology, and End User,” the bioreactors market size is expected to grow from US$ 3,643.00 million in 2022 to US$ 6,570.76 million by 2030; it is anticipated to register a CAGR of 7.65% from 2022 to 2030. Key factors such as the increasing adoption of single-use bioreactors and rapid growth of the pharmaceutical and biotechnology industry drive the market development. However, the stringent regulatory framework is hampering the market growth.

The global bioreactors market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North America regional market is expected to grow with a CAGR of 6.81% during 2022–2030. The North America bioreactors market is segmented into the US, Canada, and Mexico. The market growth in North America is attributed to the increasing demand for bioreactor systems from biopharmaceutical and biotechnology companies, the presence of market players, and growing R&D by various academic and research institutes.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPHE100000880

Rapid Growth of Pharmaceutical and Biotechnology Industry Drives the Bioreactors Market

In recent years, the pharmaceutical industry has been growing at an unprecedented pace. Big pharmaceutical companies and contract research organizations (CROs) are coming up with new medicines and therapy forms to treat a wide range of indications. The biopharmaceuticals market is increasing. The strong demand for biologics and biosimilars has driven the growth of the industry. As per the Pharmaceutical Research and Manufacturers Association (PhRMA), the US firms conduct over half the world's R&D in pharmaceuticals (US$ 75 billion) and hold the highest number of patents in new medicines. Besides growing economies, rapid growth is witnessed in the research environment in emerging economies such as Brazil, China, and India. Factors such as increasing biologics approval, growing biosimilar pipeline, and rising investment in research activities are facilitating the growth of the industry. The biopharmaceutical industry is one of the most significant contributors to the economy. Biopharmaceutical research activities are gaining pace in emerging economies such as Brazil, China, and India and offering lucrative opportunities to the market. Apart from this, increasing approvals in gene and cell therapies are favoring market growth. The approved gene therapies are Glybera-used to treat Lipoprotein Lipase Deficiency and Strimvelis- treating ADA-Severe Combined Immuno Deficiency. Thus, the factors mentioned above are increasing the demand for the large-scale production of various therapeutics, thereby facilitating the growth of the bioreactors market globally.

Applications Overview

Based on application, the bioreactors market is segmented into microbial application, cell culture application, and others. The cell culture application segment held the largest market share in 2022. However, the microbial application segment is anticipated to register the highest CAGR during the forecast period.

Microbial cultivation includes the cultivation of bacterial and viral cell cultures for various purposes, such as for basic research and development and the manufacturing of biopharmaceuticals, chemicals, and other products. The bacterial culture of E. coli is the preferred microorganism for the production of recombinant proteins. It is widely used for cloning, genetic modification, and small-scale production for research purposes. Additionally, bioreactors are crucial for the production of large-scale viral vaccines in cell culture. According to an article published by Frontiers in February 2020, bioreactors have evolved into a platform for producing various viral vectors, live viruses, and virus-based vaccines using cells. The development of fed-batch culture, perfusion culture, and genetic engineering has contributed to this advancement. In addition, the application of smart sensors and actuators to bioreactor control systems holds great promise for improving bioprocess control in the near future. As vaccine production processes have advanced, more scalable bioreactors and cell lines with high virus affinity have been utilized to produce several vaccines.

Technology-Overview

Based on technology, the bioreactors market is bifurcated into fed-batch bioreactors and perfusion bioreactors. The fed-batch bioreactors segment held a larger market share in 2022.

In fed-batch systems, fresh medium or medium components are continuously, intermittently, or singularly added while the batch volume increases over time. During fed-batch fermentation, the nutritional environment can be maintained at a consistent level. This can prevent the production of byproducts that are typically caused by high concentrations of substrate. By using this method, it is possible to extend the operating time and achieve high cell concentrations, which can lead to improved productivity (measured as mass of product per volume and time). This method is particularly useful in the production of growth-associated products. Thus, due to the advantages mentioned above, fed-batch bioreactors are used for the production of cell cultures.

Competitive Landscape

Sartorius AG, PBS Biotech, Merck KGaA, Cellexus International Ltd, General Electric Co, Thermo Fisher Scientific Inc, bbi-biotech GmbH, Pall Corp, Applikon Biotechnology BV, and Solaris Biotechnology SRL are among the leading companies operating in the bioreactors market. These companies focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which helps them to serve a large set of customers and subsequently increase their market share.

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com